Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695212 · ClinicalTrials.gov registry record · Phase 2
Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Florida Academic Dermatology Centers.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02695212 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Florida Academic Dermatology Centers. The registered enrollment target is 20 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02695212, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Florida Academic Dermatology Centers.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (1)
Florida
- Florida Academic Dermatology Centers - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02695212
The ClinicalTrials.gov registry entry for NCT02695212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The listed sponsor is Florida Academic Dermatology Centers, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT02695212 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02695212 about?
NCT02695212 is a clinical study titled "Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa". The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).
What is the current status of trial NCT02695212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-07. Estimated completion is 2017-08.
What conditions does trial NCT02695212 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT02695212?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT02695212?
This trial is sponsored by Florida Academic Dermatology Centers, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02695212 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.